Si-Bone (NASDAQ: SIBN) — Perfil da empresa, notícias e dados financeiros
Si-Bone specializes in medical devices for SI joint treatment, focusing on innovative solutions for musculoskeletal disorders.
Si-Bone
Si-Bone (NASDAQ:SIBN) specializes in innovative medical devices focusing on the surgical treatment of musculoskeletal disorders, particularly those affecting the SI (sacroiliac) joint in the pelvis. The company's flagship product, the iFuse Implant System, represents a pioneering approach to minimally invasive surgery designed to alleviate pain and improve quality of life for patients suffering from SI joint dysfunction. Si-Bone is committed to advancing healthcare by developing and delivering effective solutions that address unmet needs within orthopedic and spine surgery markets. Its objective revolves around enhancing patient outcomes and providing value to the healthcare system through clinical leadership, education, and ongoing research and development projects aimed at expanding its portfolio and improving surgical techniques.
Resumo
Operações
Produtos e/ou serviços de Si-Bone
- iFuse Implant System, a minimally invasive surgical solution for treating sacroiliac joint disorders.
- iFuse Bedrock Granite, an innovation for sacroiliac joint fusion offering immediate stabilization and long-term fusion.
- iFuse-Navigation, a system enhancing precision in sacroiliac joint fusion surgeries via 3D imaging.
- iFuse-3D, a next-generation implant featuring a 3D-printed porous titanium design for enhanced bone integration.
- Decompression and Nerve Release System, a set of tools designed for minimally invasive decompression procedures.
- iFuse-V, a vertebral body replacement device designed for spinal stabilization and reconstruction.
equipe executiva do Si-Bone
- Jeffrey W. DunnExecutive Chairman
- Laura A. FrancisCEO & Director
- Anshul MaheshwariCOO & CFO
- Michael A. PisetskyChief Business & Legal Affairs Officer, Secretary and General Counsel
- Anthony J. RecuperoAdvisor
- Scott A. YerbySenior VP of Engineering & CTO
- Ian BaileyVice President of Product & Marketing
- Daniel Joseph CherSenior Vice President of Clinical, Regulatory Affairs & Quality
- W. Carlton RecklingChief Medical Officer & VP of Medical Affairs
- Nikolas F. KerrChief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela Si-Bone, em USD.
- Cap. de mercado
- 960,9 mi
- Receita (TTM)
- 213,6 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- -6.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 200,9 mi | -22,3 mi | -18,9 mi | |
| 167,2 mi | -35,2 mi | -30,9 mi | |
| 138,9 mi | -46,9 mi | -43,3 mi | |
| 106,4 mi | -59,6 mi | -61,3 mi |